

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

CD44-APC, mouse

RRID:AB_2658154

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-110-118, RRID:AB_2658154

Antibody Information

URL: http://antibodyregistry.org/AB_2658154

Proper Citation: Miltenyi Biotec Cat# 130-110-118, RRID:AB_2658154

Target Antigen: CD44

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 1-2019; Target Distribution bone marrow, cancer cells, CNS cells, endothelial cells, epithelial cells, kidney, leukocytes, lymphocytes, mesenchymal stem cells, myeloid cells, plasma cells, ES and iPS cells, red blood cells, skeletal muscle, skin, T cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:9 µg in 300 µL

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-121. (RRID:AB_2751628).

Antibody Name: CD44-APC, mouse

Description: This monoclonal targets CD44

Target Organism: mouse

Clone ID: REA664

Antibody ID: AB_2658154

Vendor: Miltenyi Biotec

Catalog Number: 130-110-118

Record Creation Time: 20231110T034414+0000

Ratings and Alerts

No rating or validation information has been found for CD44-APC, mouse.

Warning: Discontinued: 2021

Discontinued: 1-2019; Target Distribution bone marrow, cancer cells, CNS cells, endothelial cells, epithelial cells, kidney, leukocytes, lymphocytes, mesenchymal stem cells, myeloid cells, plasma cells, ES and iPS cells, red blood cells, skeletal muscle, skin, T cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:9 µg in 300 µL

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-121. (RRID:AB_2751628).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sibilio A, et al. (2022) Immune translational control by CPEB4 regulates intestinal inflammation resolution and colorectal cancer development. iScience, 25(2), 103790.